Faculty Profiles - MIZUNO, Masashi

Papers - MIZUNO, Masashi

Division display 1 - 20 of about 350 ／ All the affair displays >>

Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. Reviewed International coauthorship International journal

Fadi Fakhouri, Andrew S Bomback, Gema Ariceta, Yahsou Delmas, Bradley P Dixon, Daniel P Gale, Larry A Greenbaum, Seung Hyeok Han, Nicole Isbel, Moglie Le Quintrec, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C Pickering, Giuseppe Remuzzi, Nicole Van De Kar, Marina Vivarelli, Patrick D Walker, Dean Wallace, Daniel Zecher, Cedric Francois, Pascal Deschatelets, Li Li, Zhongshen Wang, Lydia Abad-Franch, Nils Kinnman, Luis López-Lázaro, Johan Szamosi, Carla M Nester

The New England journal of medicine Vol. 393 ( 22 ) page： 2210 - 2220 2025.12

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis (MPGN) generally result in glomerular C3 deposition and irreversible kidney damage. The efficacy and safety of pegcetacoplan, a C3 and C3b inhibitor, in persons with C3 glomerulopathy or primary immune-complex MPGN are unclear. METHODS: We conducted a phase 3, double-blind, placebo-controlled trial involving adolescents and adults with C3 glomerulopathy or primary immune-complex MPGN, including those with native kidney disease and those with disease recurrence after transplantation. Patients were randomly assigned in a 1:1 ratio to receive pegcetacoplan or placebo. The primary end point was the log-transformed ratio of the urinary protein-to-creatinine ratio at week 26 as compared with baseline. RESULTS: A total of 124 patients underwent randomization. The change in proteinuria (as measured by the log-transformed ratio to baseline in the urinary protein-to-creatinine ratio) was significantly greater with pegcetacoplan than with placebo (geometric mean of the urinary protein-to-creatinine ratio, -67.2% [95% confidence interval {CI}, -74.9 to -57.2] vs. 2.9% [95% CI, -8.6 to 15.9]). The difference represents a relative reduction of 68.1% (95% CI, 57.3 to 76.2) as compared with placebo. In hierarchical testing of five secondary end points, significantly higher percentages of patients in the pegcetacoplan group than in the placebo group met the composite renal end-point criteria (stabilization of estimated glomerular filtration rate [eGFR] and ≥50% reduction in urinary protein-to-creatinine ratio) (49% vs. 3%) and had at least a 50% reduction in the protein-to-creatinine ratio (60% vs. 5%). Among 69 patients with evaluable kidney-biopsy samples, the change in the activity score of the C3 glomerulopathy histologic index did not differ significantly between the two groups; subsequent end points (decrease in C3 staining and change in eGFR) were not formally tested. Pegcetacoplan was not associated with more adverse events than placebo. No serious infections from encapsulated bacteria occurred; 1 patient receiving pegcetacoplan died from coronavirus disease 2019 pneumonia. No allograft rejection or loss occurred. CONCLUSIONS: Pegcetacoplan resulted in a significantly greater reduction in proteinuria than placebo among patients with C3 glomerulopathy or primary immune-complex MPGN. (Funded by Apellis Pharmaceuticals and Sobi [Swedish Orphan Biovitrum]; VALIANT ClinicalTrials.gov number, NCT05067127.).

DOI： 10.1056/NEJMoa2501510

Web of Science

PubMed

researchmap

Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model International coauthorship International journal Open Access

Kamegai, N; Kim, H; Suzuki, Y; Fukui, S; Kojima, H; Maruyama, S; Morgan, BP; Zelek, WM; Mizuno, M

CLINICAL AND EXPERIMENTAL IMMUNOLOGY Vol. 214 ( 2 ) page： 209 - 218 2023.12

Peritoneal Expression of Membrane Complement Regulators Is Decreased in Peritoneal Dialysis Patients with Infected Peritonitis Invited Reviewed International journal Open Access

Fukui Sosuke, Mizuno Masashi, Tawada Mitsuhiro, Suzuki Yasuhiro, Kojima Hiroshi, Matsukawa Yoshihisa, Imai Masaki, Kim Hangsoo, Kinashi Hiroshi, Mizutani Makoto, Minoshima Kenichi, Maruyama Shoichi, Ito Yasuhiko

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Vol. 24 ( 11 ) 2023.5

Serum and plasma levels of Ba, but not those of soluble C5b-9, might be affected by renal function in chronic kidney disease patients Reviewed International journal Open Access

Yamane, R; Yasuda, Y; Oshima, A; Suzuki, Y; Kojima, H; Kim, H; Fukui, S; Maruyama, S; Ito, Y; Mizuno, M

BMC NEPHROLOGY Vol. 24 ( 1 ) page： 26 2023.2

Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry International journal Open Access

Nakagawa, N; Mizuno, M; Kato, S; Maruyama, S; Sato, H; Nakaya, I; Sugiyama, H; Fujimoto, S; Miura, K; Matsumura, C; Gotoh, Y; Suzuki, H; Kuroki, A; Yoshino, A; Nakatani, S; Hiromura, K; Yamamoto, R; Yokoyama, H; Narita, I; Isaka, Y

PLOS ONE Vol. 16 ( 9 ) page： e0257397 2021.9

C1 inhibitor mitigates peritoneal injury in zymosan-induced peritonitis. Reviewed International journal

Toshikazu Ozeki, Masashi Mizuno, Daiki Iguchi, Hiroshi Kojima, Hangsoo Kim, Yasuhiro Suzuki, Hiroshi Kinashi, Takuji Ishimoto, Shoichi Maruyama, Yasuhiko Ito

American journal of physiology. Renal physiology Vol. 320 ( 6 ) page： F1123 - F1132 2021.6

Authorship：Corresponding author Language：English Publishing type：Research paper (scientific journal)

Peritonitis, due to a fungal or bacterial infection, leads to injury of the peritoneal lining and thereby forms a hazard for the long-term success of peritoneal dialysis (PD) and remains a lethal complication in patients with PD. This study investigated whether C1 inhibitor (C1-INH) could protect against the progression of peritoneal injuries with five daily administrations of zymosan after mechanical scraping of the rat peritoneum to mimic fungal peritonitis. Severe peritoneal injuries were seen in this model, accompanied by fibrinogen/fibrin exudation and peritoneal deposition of complement activation products such as activated C3 and C5b-9. However, intraperitoneal injection of C1-INH decreased peritoneal depositions of activated C3 and C5b-9, ameliorated peritoneal thickening, reduced the influx of inflammatory cells, and prevented the production of peritoneal fibrous layers with both one and two doses of C1-INH each day. Our results suggest that C1-INH might be useful to protect against peritoneal injuries after causes of peritonitis such as fungal infection. This clinically available agent may thus help extend the duration of PD.NEW & NOTEWORTHY Peritoneal injuries associated with peritonitis comprise an important issue to prevent long-term peritoneal dialysis (PD) therapy. Here, we showed that C1 inhibitor (C1-INH), as an anticomplement agent, protected against peritoneal injuries in a peritonitis animal model related to fungal infection. Therefore, C1-INH might be useful to protect against peritoneal injuries after peritonitis due to fungal infection. This clinically available agent may thus help extend the duration of PD.

DOI： 10.1152/ajprenal.00600.2020

Web of Science

PubMed

researchmap

Eculizumab for pediatric dense deposit disease: A case report and literature review. Reviewed International journal Open Access

Katsuaki Kasahara, Yoshimitsu Gotoh, Hisakazu Majima, Asami Takeda, Masashi Mizuno

Clinical nephrology. Case studies Vol. 8 page： 96 - 102 2020

Authorship：Last author Language：English Publishing type：Research paper (scientific journal)

Dense deposit disease (DDD), a subtype of complement component 3 (C3) glomerulopathy (C3G), results from alternative complement pathway hyperactivity leading to membrane attack complex formation. DDD treatment strategies are limited. We report a case of a 13-year-old girl diagnosed with DDD at 9 years of age, with nephritic and nephrotic syndrome and C3 nephritic factor-negative alternative complement pathway activation. Initial treatment with prednisolone, methylprednisolone pulses (MPs), and mizoribines was effective for 3 years, after which she relapsed. Despite MP treatment followed by prednisolone and mycophenolate mofetil (MMF), her kidney function and proteinuria deteriorated with a high soluble (s)C5b-9 level; she also developed dyspnea and pleural effusion (PE). Three days after the first eculizumab (ECZ) infusion, urine volume increased, respiratory condition improved, PE resolved, and proteinuria decreased in 1 month. Serum creatinine level decreased, and kidney function completely normalized within 7 weeks. The sC5b-9 level normalized, and although proteinuria decreased, nephrotic range proteinuria persisted during ECZ treatment with MMF for 53 weeks, even with increased treatment interval. Thus, complement activation pathway-targeted therapy may be useful for rapidly progressing DDD. Our data support the role of complement pathway abnormalities in C3G with DDD.

DOI： 10.5414/CNCS110309

Open Access

PubMed

researchmap

Connective tissue growth factor is correlated with peritoneal lymphangiogenesis. Reviewed International coauthorship International journal Open Access

Hiroshi Kinashi, Naohiro Toda, Ting Sun, Tri Q Nguyen, Yasuhiro Suzuki, Takayuki Katsuno, Hideki Yokoi, Jan Aten, Masashi Mizuno, Shoichi Maruyama, Motoko Yanagita, Roel Goldschmeding, Yasuhiko Ito

Scientific reports Vol. 9 ( 1 ) page： 12175 - 12175 2019.8

Language：English Publishing type：Research paper (scientific journal)

Lymphatic absorption in the peritoneal cavity may contribute to ultrafiltration failure in peritoneal dialysis (PD). Lymphatic vessels develop during PD-related peritoneal fibrosis. Connective tissue growth factor (CTGF, also called CCN2) is an important determinant of fibrotic tissue remodeling, but little is known about its possible involvement in lymphangiogenesis. In this study, we investigated the relationship between CTGF and peritoneal lymphangiogenesis. A positive correlation was observed between vascular endothelial growth factor-C (VEGF-C), a major lymphangiogenic growth factor, and the CTGF concentration in human PD effluents. CTGF expression was positively correlated with expression of lymphatic markers and VEGF-C in human peritoneal biopsies. We found a positive correlation between the increase in CTGF and the increase in VEGF-C in cultured human peritoneal mesothelial cells (HPMCs) treated with transforming growth factor-β1 (TGF-β1). The diaphragm is a central player in peritoneal lymphatic absorption. CTGF expression was also correlated with expression of VEGF-C and lymphatics in a rat diaphragmatic fibrosis model induced by chlorhexidine gluconate (CG). Furthermore, CTGF gene deletion reduced VEGF-C expression and peritoneal lymphangiogenesis in the mouse CG model. Inhibition of CTGF also reduced VEGF-C upregulation in HPMCs treated with TGF-β1. Our results suggest a close relationship between CTGF and PD-associated lymphangiogenesis.

DOI： 10.1038/s41598-019-48699-9

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Reviewed International journal Open Access

Shuichi Ito, Yoshihiko Hidaka, Norimitsu Inoue, Shinya Kaname, Hideki Kato, Masanori Matsumoto, Yoshitaka Miyakawa, Masashi Mizuno, Hirokazu Okada, Akihiko Shimono, Takahisa Matsuda, Shoichi Maruyama, Yoshihiro Fujimura, Masaomi Nangaku, Shoji Kagami

Clinical and experimental nephrology Vol. 23 ( 1 ) page： 112 - 121 2019.1

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: In 2013, eculizumab was approved for treatment of the atypical hemolytic-uremic syndrome (aHUS) in Japan, which was defined as a thrombotic microangiopathy (TMA) excluding Shiga toxin-producing Escherichia coli-HUS and thrombotic thrombocytopenic purpura. Simultaneously, post-marketing surveillance was started to assess its safety and effectiveness. In 2016, Japanese clinical guide redefined terms to limit the use of "aHUS" to complement-mediated HUS only. Accordingly, TMA with other causes was defined as secondary TMA. Here we report the interim analysis of post-marketing surveillance of pediatric patients with aHUS and secondary TMA. METHODS: Pediatric patients treated with eculizumab from approval to 15 March 2017 were included in this observational real-world study. Clinical endpoints of effectiveness were TMA event-free status, complete TMA response, platelet count normalization, and improvement of estimated glomerular filtration rate (eGFR). Adverse reactions to eculizumab were also analyzed. RESULTS: In 27 pediatric patients with aHUS, median age at diagnosis was 4 years. Complement genes' variants were detected in 14 of 21 patients (66.7%). Median time from diagnosis to eculizumab initiation was 2.0 days. TMA event-free status, complete TMA response, platelet normalization, and improvement in eGFR were achieved in 85.2, 36.4, 78.3, and 75.0% of patients, respectively. Three patients with aHUS died. Twenty-four and 10 adverse reactions were reported in 31 aHUS patients and 17 secondary TMA patients, respectively; however, no eculizumab-related death or meningococcal infection was reported. CONCLUSIONS: This interim analysis confirmed that eculizumab is well-tolerated and effective for Japanese pediatric patients with aHUS in a real-world setting.

DOI： 10.1007/s10157-018-1610-2

Increase of Eosinophil in Dialysate During Induction of Peritoneal Dialysis. Reviewed International journal Open Access

Shigemoto E, Mizuno M, Suzuki Y, Kobayashi K, Sakata F, Kariya T, Katsuno T, Maruyama S, Ito Y

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis Vol. 39 ( 1 ) page： 90 - + 2019.1

Anti-C5a complementary peptide mitigates zymosan-induced severe peritonitis with fibrotic encapsulation in rats pretreated with methylglyoxal Reviewed International journal Open Access

Daiki Iguchi, Masashi Mizuno, Yasuhiro Suzuki, Fumiko Sakata, Shoichi Maruyama, Alan Okada, Hidechika Okada, Yasuhiko Ito

American Journal of Physiology - Renal Physiology Vol. 315 ( 6 ) page： F1732 - F1746 2018.12

Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology Invited Reviewed International journal

Masashi Mizuno, Yasuhiro Suzuki, Yasuhiko Ito

Clinical and Experimental Nephrology Vol. 22 ( 1 ) page： 3 - 14 2018.2

Authorship：Lead author,　Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：Springer Tokyo

The complement activation system plays important roles to maintain homeostasis in the host and to fight foreign invaders to protect the host. Therefore, the complement system is considered a core part of innate immunity which also cross-talks to acquired immunity. In the history of nephrology, the complement system is familiar to us, because complement protein or fragment deposition, including C3, C4, C1q, and/or C4d, is routinely estimated by immunohistochemistry to diagnose renal pathologies. The relationships between pathological mechanisms and complement activation have been investigated for renal diseases such as post-infectious glomerulonephritis, lupus nephritis, and primary membranoproliferative glomerulonephritis, which are usually accompanied by hypocomplementemia. However, unregulated complement activation in local areas might be associated with progression of various renal injuries even in the normocomplementemic patient. Recently, attention has focused on dysfunction of complement regulation in various diseases including renal diseases such as atypical hemolytic uremic syndrome and C3 glomerulopathy. Some mechanisms associated with complement activation in these diseases were clarified. In addition, lots of anti-complement agents were developed and some of the agents have become clinically available. Now, anti-complement therapies represent a realistic choice of therapeutic approaches for complement-related diseases. Research on roles of complement activation is proceeding into new stages in the field of nephrology and in other fields involving both basic and clinical research. We herein summarize relationships between the complement activation and regulation systems, their physiological effects and roles in maintenance of homeostasis in the host, and how dysregulation of the complement system triggers disease, especially renal disease.

DOI： 10.1007/s10157-017-1405-x

Mesangial proliferative glomerulonephritis in murine malaria parasite, Plasmodium chabaudi AS, infected NC mice Reviewed International journal Open Access

Akihito Yashima, Masashi Mizuno, Yukio Yuzawa, Koki Shimada, Norihiko Suzuki, Hideo Tawada, Waichi Sato, Naotake Tsuboi, Shoichi Maruyama, Yasuhiko Ito, Seiichi Matsuo, Tamio Ohno

CLINICAL AND EXPERIMENTAL NEPHROLOGY Vol. 21 ( 4 ) page： 589 - 596 2017.8

Authorship：Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：SPRINGER

Background Malaria is an important tropical disease and has remained a serious health problem in many countries. One of the critical complications of malarial infection is renal injury, such as acute renal failure and chronic glomerulopathy. Few animal models of nephropathy related to malarial infection have been reported. Therefore, we developed and investigated a novel malarial nephropathy model in mice infected by murine malaria parasites.
Methods NC mice and C57BL/6J mice were infected with Ttwo different murine malaria parasites, Plasmodium (P.) chabaudi AS and P. yoelii 17X. After the infection, renal pathology and blood and urinary biochemistry were analyzed.
Results NC mice infected by the murine malaria parasite P. chabaudi AS, but not P. yoelii 17X, developed mesangial proliferative glomerulonephritis with endothelial damage, and decreased serum albumin concentration and increased proteinuria. These pathological changes were accompanied by deposition of immunoglobulin G and complement component 3, mainly in the mesangium until day 4 and in the mesangium and glomerular capillaries from day 8. On day 21, renal pathology developed to focal segmental sclerosis according to light microscopy. In C57BL/6J mice, renal injuries were not observed from either parasite infection.
Conclusion The clinical and pathological features of P. chabaudi AS infection in NC mice might be similar to quartan malarial nephropathy resulting from human malaria parasite P. malariae infection. The NC mouse model might therefore be useful in analyzing the underlying mechanisms and developing therapeutic approaches to malaria-related nephropathy.

DOI： 10.1007/s10157-016-1339-8

High Levels of Soluble C5b-9 Complex in Dialysis Fluid May Predict Poor Prognosis in Peritonitis in Peritoneal Dialysis Patients Reviewed International coauthorship International journal Open Access

Masashi Mizuno, Yasuhiro Suzuki, Keiko Higashide, Yumi Sei, Daiki Iguchi, Fumiko Sakata, Masanobu Horie, Shoichi Maruyama, Seiichi Matsuo, B. Paul Morgan, Yasuhiko Ito

PLOS ONE Vol. 12 ( 1 ) page： e0169111 2017.1

Authorship：Lead author,　Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：PUBLIC LIBRARY SCIENCE

Background
We searched for indicators to predict the prognosis of infectious peritonitis by measuring levels of complement proteins and activation products in peritoneal dialysis (PD) fluid (PDF) of patients at early stages of peritonitis. We retrospectively analyzed the relationship between the levels of sC5b-9, C3 and C4 in PDF and the subsequent clinical prognosis.
Methods
We measured levels of sC5b-9, C3 and C4 in PDF on days 1, 2 and 5 post-onset of peritonitis in 104 episodes of infectious peritonitis in PD patients from 2008 and retrospectively compared levels with clinical outcomes. Further analysis for the presence of causative microorganisms or to demonstrate bacterial culture negative peritonitis was performed and correlated with change of levels of sC5b-9 in PDF.
Results
When PD patients with peritonitis were divided into groups that either failed to recover from peritonitis and were finally withdrawn from PD (group 1; n = 25) or recovered (group 2; n = 79), levels of sC5b-9, C3 and C4 in PDF were significantly higher in group 1 patients compared to those in group 2 on day5. Analysis of microorganisms showed significantly higher sC5b-9 levels in PDF of peritonitis cases caused by culture negative peritonitis in group 1 compared with group 2 when we analyzed for individual microorganisms. Of note, on day5, the sC5b- 9 levels in PDF were similarly high in peritonitis caused by fungi or other organisms.
Conclusion
Our results suggested that levels of complement markers in PDF, especially sC5b- 9, have potential as surrogate markers to predict prognosis of PD-related peritonitis.

DOI： 10.1371/journal.pone.0169111

Recent analysis of status and outcomes of peritoneal dialysis in the Tokai area of Japan: the second report of the Tokai peritoneal dialysis registry Reviewed International journal Open Access

Masashi Mizuno, Yasuhiko Ito, Yasuhiro Suzuki, Fumiko Sakata, Yosuke Saka, Takeyuki Hiramatsu, Hirofumi Tamai, Makoto Mizutani, Tomohiko Naruse, Norimi Ohashi, Hirotake Kasuga, Hideaki Shimizu, Hisashi Kurata, Kei Kurata, Satoshi Suzuki, Satoko Kido, Yoshikazu Tsuruta, Teppei Matsuoka, Masanobu Horie, Shoichi Maruyama, Seiichi Matsuo

CLINICAL AND EXPERIMENTAL NEPHROLOGY Vol. 20 ( 6 ) page： 960 - 971 2016.12

Authorship：Lead author,　Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：SPRINGER

Early withdrawal within 3 years after starting peritoneal dialysis (PD) and PD-related peritonitis have been major obstacles preventing increases in the population of PD patients. To address these problems, we implemented education programs for medical staff. This study analyzed the recent status and outcomes of PD therapy, focusing on findings such as the incidence and prognosis of peritonitis as of 5 years after our last study.
We investigated background, laboratory data and status of PD therapy, reasons for withdrawal from PD and incidental statements on peritonitis from 2010 to 2012 (R2), and compared findings with those from our last study of 2005-2007 (R1).
Early PD therapy withdrawal in R2 clearly improved to 44.7 %, compared with 50.9 % in R1. Peritonitis incidence improved slightly from once per 42.8 months/patient in R1 to once per 47.3 months/patient in R2. Notably, PD-related peritonitis as a cause of mortality improved markedly in R2, but outcomes of PD-related peritonitis did not change significantly between R1 and R2. In contrast, social problems increased as a reason for withdrawal from PD therapy.
Our efforts at education might have been useful for improving early withdrawal from PD and deaths attributable to PD-related peritonitis. However, since improvements to incidence of PD-related peritonitis were limited by education, further improvement in PD-related peritonitis incidence requires development of new sterilized connecting systems during PD-bag exchanges to decrease PD-related peritonitis opportunities. Construction of medical support systems to address social problems is required to maintain long-term PD therapy.

DOI： 10.1007/s10157-016-1249-9

Expression of membrane complement regulators, CD46, CD55 and CD59, in mesothelial cells of patients on peritoneal dialysis therapy Reviewed International coauthorship International journal

Yumi Sei, Masashi Mizuno, Yasuhiro Suzuki, Masaki Imai, Keiko Higashide, Claire L. Harris, Fumiko Sakata, Daiki Iguchi, Michitaka Fujiwara, Yasuhiro Kodera, Shoichi Maruyama, Seiichi Matsuo, Yasuhiko Ito

MOLECULAR IMMUNOLOGY Vol. 65 ( 2 ) page： 302 - 309 2015.6

Authorship：Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：PERGAMON-ELSEVIER SCIENCE LTD

We investigated the expression of membrane complement regulators (CRegs), CD46, CD55 and CD59 in human mesothelial cells, and correlated with clinical background and level of complement (C) activation products in peritoneal dialysis (PD) fluids (PDF) to clarify influence of the C activation system in PD patients. Expression of CRegs was assessed on primary cultures of mesothelial cells (HPMC) harvested from PD fluid of 31 PD patients. Because expression of CD55 but not CD46 and CD59 in mesothelial cells was significantly correlated to value of dialysate-to-plasma creatinine concentration ratio (D/P Cre) (p<0.005) as an indicator of peritoneal function, we focused on analysis of CD55 expression of HPMCs in comparison with levels of C activation products in the PDF of the PD patients, and their background factors. When comparing expression of the CRegs between systemic neutrophils and HPMC, no correlation was observed, supporting that change of CRegs' expression in HPMC was independently occurring in the peritoneum. Expression of CD55 protein in HPMC was closely correlated with expression at the mRNA level (p<0.0001) and was inversely correlated with levels of sC5b-9 (p<0.05), but not C3, C4, IL6 and CA125 in the PDF. Complications of diabetes, usage of icodextrin and residual renal function were not correlated with change of CD55 expression in HPMCs.
Our data show that the process of PD therapy modifies expression of CD55 on peritoneal mesothelium and triggers local C activation. These findings support efforts to modify PD therapy to limit effects on activation and regulation of the C system. (C) 2015 Elsevier Ltd. All rights reserved.

DOI： 10.1016/j.molimm.2015.02.005

Web of Science

PubMed

researchmap

Long-Term Effects of Spironolactone in Peritoneal Dialysis Patients Reviewed International journal Open Access

Ito Yasuhiko, Mizuno Masashi, Suzuki Yasuhiro, Tamai Hirofumi, Hiramatsu Takeyuki, Ohashi Hiroshige, Ito Isao, Kasuga Hirotake, Horie Masanobu, Maruyama Shoichi, Yuzawa Yukio, Matsubara Tatsuaki, Matsuo Seiichi

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY Vol. 25 ( 5 ) page： 1094 - 1102 2014.5

Anti-C5a complementary peptide ameliorates acute peritoneal injuries induced by neutralization of Crry and CD59. Reviewed

Mizuno T, Mizuno M, Imai M, Suzuki Y, Kushida M, Noda Y, Maruyama S, Okada H, Okada N, Matsuo S, Ito Y.

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY Vol. 305 ( 11 ) page： F1603 - F1616 2013

Guideline for Hereditary Angioedema (HAE) 2010 by the Japanese Association for Complement Research - Secondary Publication Reviewed International journal Open Access

Horiuchi Takahiko, Ohi Hiroyuki, Ohsawa Isao, Fujita Teizo, Matsushita Misao, Okada Noriko, Seya Tsukasa, Yamamoto Tetsuro, Endo Yuichi, Hatanaka Michiyo, Wakamiya Nobutaka, Mizuno Masashi, Nakao Miki, Okada Hidechika, Tsukamoto Hiroshi, Matsumoto Misako, Inoue Norimitsu, Nonaka Masaru, Kinoshita Taroh

Allergology International Vol. 61 ( 4 ) page： 559 - 562 2012.12

Language：English Publishing type：Research paper (scientific journal) Publisher：Japanese Society of Allergology

This guideline was provided by the Japanese Association for Complement Research targeting clinicians for making an accurate diagnosis of hereditary angioedema (HAE), and for prompt treatment of the HAE patient in Japan. This is a 2010 year version and will be updated according to any pertinent medical advancements.<br>

DOI： 10.2332/allergolint.12-RAI-0471

Exploiting the Nephrotoxic Effects of Venom from the Sea Anemone, Phyllodiscus semoni, to Create a Hemolytic Uremic Syndrome Model in the Rat Invited Reviewed International coauthorship International journal Open Access

Masashi Mizuno, Yasuhiko Ito, B. Paul Morgan

MARINE DRUGS Vol. 10 ( 7 ) page： 1582 - 1604 2012.7

Authorship：Lead author,　Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：MDPI AG

In the natural world, there are many creatures with venoms that have interesting and varied activities. Although the sea anemone, a member of the phylum Coelenterata, has venom that it uses to capture and immobilise small fishes and shrimp and for protection from predators, most sea anemones are harmless to man. However, a few species are highly toxic; some have venoms containing neurotoxins, recently suggested as potential immune-modulators for therapeutic application in immune diseases. Phyllodiscus semoni is a highly toxic sea anemone; the venom has multiple effects, including lethality, hemolysis and renal injuries. We previously reported that venom extracted from Phyllodiscus semoni induced acute glomerular endothelial injuries in rats resembling hemolytic uremic syndrome (HUS), accompanied with complement dysregulation in glomeruli and suggested that the model might be useful for analyses of pathology and development of therapeutic approaches in HUS. In this mini-review, we describe in detail the venom-induced acute renal injuries in rat and summarize how the venom of Phyllodiscus semoni could have potential as a tool for analyses of complement activation and therapeutic interventions in HUS.

DOI： 10.3390/md10071582

　 PREV - NEXT 　

<MIZUNO, Masashi>

Papers - MIZUNO, Masashi